Table 1 A. Patient baseline characteristics. B Genomic alterations of patients with ≥1 targetable alteration*.
TABLE 1A. Patient Baseline Characteristics | Group | No. of patients, Part A (%) | No. of patients, Part B (%) | Total no. of patients (%) |
|---|---|---|---|---|
(N = 391) | (N = 209) | (N = 600) | ||
Age, years | <60 | 194 (49.6) | 118 (56.5) | 312 (52.0) |
≥60 | 197 (50.4) | 91 (43.5) | 288 (48.0) | |
Gender | Female | 197 (50.4) | 112 (53.6) | 309 (51.5) |
Male | 194 (49.6) | 97 (46.4) | 291 (48.5) | |
No. of prior therapies | ≤3 | 234 (59.8) | 84 (40.2) | 318 (53.0) |
>3 | 151 (38.6) | 125 (59.8) | 276 (46.0) | |
UNK | 6 (1.5) | 0 | 6 (1.0) | |
PS | 0 | 50 (12.8) | 30 (14.4) | 80 (13.3) |
1 | 341 (87.2) | 179 (85.6) | 520 (86.7) | |
No. of metastatic sites | 0–2 | 234 (59.8) | 129 (61.7) | 363 (60.5) |
>2 | 157 (40.2) | 79 (37.8) | 236 (39.3) | |
UNK | 0 | 1 (0.5) | 1 (0.2) | |
Liver metastases | No | 236 (60.4) | 113 (54.1) | 349 (58.2) |
Yes | 155 (39.6) | 95 (45.5) | 250 (41.7) | |
UNK | 0 | 1 (0.5) | 1 (0.2) | |
PLT count, x 109/L | <140 | 43 (11.0) | 30 (14.4) | 73 (12.2) |
140–440 | 334 (85.4) | 169 (80.9) | 503 (83.3) | |
>440 | 14 (3.6) | 6 (2.9) | 20 (3.3) | |
UNK | 0 | 4 (1.9) | 4 (0.7) | |
Alb, g/dL | <3.5 | 35 (9.0) | 19 (9.1) | 54 (9.0) |
≥3.5 | 356 (91.0) | 186 (89.0) | 542 (90.3) | |
UNK | 0 | 4 (1.9) | 4 (0.7) | |
LDH, IU/L | ≤ULN | 270 (69.1) | 91 (43.5) | 361 (60.2) |
>ULN | 96 (24.6) | 94 (45.0) | 190 (31.7) | |
UNK | 25 (6.4) | 24 (11.5) | 49 (8.2) |
TABLE 1B. B Genomic Alterations of Patients with ≥1 Targetable Alterations by Pathway | No. of patients, Part A | No. of patients, Part B | Total no. of patients |
|---|---|---|---|
(N = 317) | (N = 157) | (N = 474) | |
PI3K/Akt/mTOR pathway | 105 (33.1) | 41 (26.1) | 146 (30.8) |
MAPK signaling | 88 (27.7) | 47 (29.9) | 135 (28.4) |
Tyrosine kinases | 53 (16.7) | 29 (15.5) | 82 (17.2) |
TP53 | 161 (50.8%) | 69 (43.9%) | 230 (48.5%) |
Other (non-p53) tumor suppressor/apoptosis–associated genes | 38 (12.0%) | 10 (6.4%) | 48 (10.1%) |
Cell cycle–associated genes | 128 (40.3) | 37 (23.6) | 165 (34.8) |
Hormone pathway | 7 (2.2) | 1 (0.6) | 8 (1.7) |
DNA repair pathway | 15 (4.7) | 4 (2.5) | 19 (4.0) |
